Ipamorelin / CJC-1295 No Dac 10mg

CJC-1295 (No DAC) is a synthetic peptide based on the receptor-active segment of endogenous growth hormone–releasing hormone, encompassing its initial 29 amino acids (4,14). Structural modifications were introduced to enhance stability against enzymatic degradation while maintaining strong specificity for the GHRH receptor expressed on pituitary somatotroph cells (3). This selective receptor interaction enables reproducible activation of intracellular signaling pathways associated with growth hormone synthesis and secretion (10). Owing to its increased resistance to proteolysis and consistent receptor engagement, CJC-1295 (No DAC) is commonly utilized in experimental models to investigate GHRH mediated signaling and regulatory mechanisms governing growth hormone release (15).

Ipamorelin is a short-chain, synthetically produced peptide composed of five amino acids that functions as a targeted activator of the growth hormone secretagogue receptor subtype 1a (GHSR-1a) (1,6). It was specifically designed to replicate ghrelin-associated growth hormone signaling while maintaining a narrow receptor interaction profile (11). Unlike earlier secretagogues with broader endocrine activity, Ipamorelin demonstrates a high degree of selectivity for GHSR-1a, allowing researchers to examine ghrelin-mediated intracellular pathways with reduced interference from parallel pituitary hormone systems (5). Engagement of this receptor primarily initiates phospholipase C dependent signaling and intracellular calcium mobilization within somatotroph cells, supporting its utility in mechanistic investigations of growth hormone release dynamics (7,13). Due to its receptor specificity and predictable signaling behavior, Ipamorelin is frequently incorporated into in vitro and preclinical models aimed at studying hypothalamic pituitary communication, signal transduction fidelity, and temporal hormone secretion patterns under controlled experimental conditions (11,15).

Mechanism of action

CJC-1295 (No DAC) engages the growth hormone, releasing hormone receptor (GHRHR), leading to activation of Gₛ protein coupled signaling. This stimulates adenylate cyclase activity, resulting in elevated intracellular cyclic AMP levels and downstream activation of protein kinase A, which supports growth hormone related cellular responses.

Ipamorelin selectively binds to the growth hormone secretagogue receptor type 1a (GHSR-1a), triggering Gq/11-dependent signaling pathways. This interaction activates phospholipase C, promotes inositol triphosphate formation, and induces the release of calcium from intracellular stores, contributing to growth hormone secretory processes.

Concurrent evaluation of both peptides allows researchers to examine how cAMP-driven and calcium-dependent signaling pathways operate simultaneously within pituitary somatotrophs, providing a controlled model for studying pathway integration, receptor cross-communication, and endocrine signal coordination. Here is the representataion of its mechanistic pathway in form of flowchart and diagram.

Research Applications of the CJC-1295 and Ipamorelin Blend

• Dual-receptor signaling analysis (GHRHR and GHSR-1a)
  The combined use of CJC-1295 and Ipamorelin enables simultaneous activation of growth hormone–releasing hormone receptors (GHRHR) and ghrelin receptors (GHSR-1a), providing an experimental model to study parallel receptor engagement and convergence at the level of pituitary somatotroph signaling. (14,16)
• Pulsatile endocrine signaling and receptor cross-talk studies
  By engaging mechanistically distinct receptor systems, this peptide pairing supports investigation of growth hormone pulsatility and temporal coordination of endocrine signals. Preclinical studies have shown that co-activation of GHRHR and GHSR-1a offers insight into receptor cross-talk and integrated hypothalamic–pituitary regulation(17,18)
• Evaluation of cAMP- and Ca²⁺-dependent second messenger pathways
  CJC-1295 primarily stimulates Gₛ-coupled signaling pathways leading to increased intracellular cAMP, whereas Ipamorelin activates Gq/11-linked signaling and calcium mobilization. Their combined application allows comparative assessment of second messenger dynamics and intracellular signal integration in endocrine research systems. (19,20).
• Downstream IGF-axis modulation in preclinical models
  In experimental settings, upstream modulation of growth hormone secretion using CJC-1295 and Ipamorelin has been employed to explore mechanistic relationships between pituitary signaling and downstream components of the insulin-like growth factor axis, focusing on pathway regulation rather than therapeutic interpretation. (21,22)

Preclinical Research Summary

Experimental investigations conducted in controlled laboratory settings have extensively explored growth hormone regulating peptides, including growth hormone releasing hormone analogues and ghrelin receptor agonists, to elucidate fundamental mechanisms of endocrine regulation. Using in vitro systems and animal based models, these studies have focused on characterizing receptor specificity, intracellular signaling fidelity, and the temporal organization of hormone secretion.

Within these preclinical frameworks, particular attention has been given to how distinct receptor pathways contribute to pulsatile growth hormone release and how parallel signaling inputs are integrated at the level of pituitary somatotrophs. Cellular assays have enabled detailed examination of second messenger dynamics, such as cyclic AMP generation and calcium mobilization, while animal models have provided insight into systemic signal coordination and feedback regulation along the hypothalamic pituitary axis.

Importantly, all observations derived from this body of research originate from non-human and non-clinical experimental environments. The findings are intended to advance mechanistic understanding of endocrine signaling architecture and regulatory complexity, rather than to inform therapeutic use or clinical application.

References

1. Smith RG, Van der Ploeg LH, Howard AD, et al. Peptidomimetic regulation of growth hormone secretion. Endocr Rev. 1997;18(5):621–645.
2. Thorner MO, Vance ML, Laws ER, Horvath E, Kovacs K. The anterior pituitary. In: Williams Textbook of Endocrinology. 10th ed. Philadelphia: Saunders; 2003. p. 249–340.
3. Momany FA, Bowers CY, Reynolds GA, et al. Design, synthesis, and biological activity of growth hormone-releasing hormone analogs. Endocrinology. 1984;114(5):1531–1536.
4. Frohman LA, Jansson JO. Growth hormone-releasing hormone. Endocr Rev. 1986;7(3):223–253.
5. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, a selective growth hormone secretagogue with minimal endocrine side effects. J Endocrinol. 2001;170(2):435–443.
6. Howard AD, Feighner SD, Cully DF, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974–977.
7. Muller EE, Locatelli V, Cocchi D. Neuroendocrine control of growth hormone secretion. Physiol Rev. 1999;79(2):511–607.
8. Thorner MO, et al. Growth hormone–releasing hormone and regulation of growth hormone secretion. Endocr Rev. 1996;17(6):671–728.
9. Vance ML, Kaiser DL, Frohman LA, Rivier J, Vale W. Dual secretagogue regulation of growth hormone release. J Clin Endocrinol Metab. 1985;60(3):522–528.
10.  Mayo KE, Miller T, DeAlmeida V, et al. Regulation of growth hormone gene expression by GHRH. Recent Prog Horm Res. 2000;55:257–283.
11.  Bednarek MA, et al. Structure–function studies of ghrelin receptor agonists. J Med Chem. 2000;43(23):4370–4376.
12.  Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion. J Endocrinol Invest. 1998;21(9):585–594.
13. Kojima M, Kangawa K. Ghrelin: structure and biological actions. Physiol Rev. 2005;85(2):495–522.
14.  Thorner MO, et al. Growth hormone–releasing hormone and the regulation of growth hormone secretion. Endocr Rev. 1996;17(6):671–728.
15. Giustina A, Veldhuis JD. Pathophysiology of the neuroregulation of growth hormone secretion. J Endocrinol Invest. 1998;21(9):585–594.
16. Mayo KE, Miller LJ, Bataille D, Dalle S, Göke B, Thorens B, et al. International Union of Pharmacology. XXXV. The glucagon receptor family. Pharmacol Rev. 2003;55(1):167-194.
17. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660.
18. Smith RG, Sun Y, Betancourt L, Asnicar M. Growth hormone secretagogues: receptor specificity and signal transduction. Endocrine. 2005;28(1):3-14.
19. Gaylinn BD. Regulation of growth hormone secretion by GHRH and ghrelin signaling pathways. Endocrinol Metab Clin North Am. 2017;46(2):211-224.
20. van der Lely AJ, Tschöp M, Heiman ML, Ghigo E. Biological, physiological, pathophysiological and pharmacological aspects of ghrelin. Endocr Rev. 2004;25(3):426-457.
21.  Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev. 2001;22(1):53-74.
22. Brooks AJ, Waters MJ. The growth hormone receptor: mechanism of activation and implications for signal transduction. Nat Rev Endocrinol. 2010;6(9):515-525.